NCT Number: NCT00380744
A Safety and Pharmacokinetics Study in Participants With Rheumatoid Arthritis
The purpose of this study is to examine the safety and efficacy of this antibody in participants with rheumatoid arthritis.
Part A of the study is an initial dose escalation phase
Part B of the study is a randomized allocation of the entire dosing group to parallel treatment assignments
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1 / Phase 2
Primary location
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bialystok, Poland
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- diagnosis of rheumatoid arthritis
- regular use of methotrexate
- active rheumatoid arthritis
Exclusion criteria
- Juvenile Rheumatoid Arthritis
- evidence of tuberculosis
- women who are pregnant or become pregnant during study, or are breast-feeding
Treatment and study plan
Placebo
DrugPrimary outcomes
-
Number of Participants With Adverse Events (AEs)
Time frame: Baseline up to Day 98
Clinically significant events were defined as serious AEs (SAEs) and other non-serious AEs regardless of causality. A summary of s SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Secondary outcomes
-
Pharmacokinetics (PK): Area Under the Concentration Time Curve at Steady State for One Dosing Interval Time 0 to 168 Hours (AUC0-168 hr,ss) of LY2189102
Time frame: Part A: Day 1 predose and IAI, 2days post infusion, Day 14 and Day 28 predose and IAI, Day 35, 63 (convenient time)
AUC0-168 hr,ss of individual participants was calculated by equation AUC=Dose/Clearance (CL), where the CL was estimated using a population PK model.
Time frame for Part B: Day 1 predose, immediately after infusion (IAI), Day 14 and 28: predose and IAI, and Day 63 (Convenient time);
-
Change From Baseline in Simple Disease Activity Index Score (SDAI)
Time frame: Baseline, Days 7, 21, 35, 63, and 98
SDAI is calculated as the sum of 5 components: tender joint count (TJC) and swollen joint count (SJC), Patient Global Assessment (PtGA) of disease activity visual analog scale (VAS) and Physician's Global Assessment of Disease Activity (PGA) VAS, and C-reactive protein (CRP). Total Score scale range is 0 (remission) to 86 (high disease activity). A negative change from baseline indicated an improvement. Least Squares (LS) mean calculated using a repeated measures model and adjusted for baseline + treatment + time + treatment * time.
-
Change From Baseline in Disease Activity Score 28-Joint Count (DAS28)
Time frame: Baseline, Days 7, 21, 35, 63, and 98
DAS28-4 (crp) is a modification of the original DAS based on TJC and SJC based on 28 joint counts, PGA VAS. DAS28-4 (crp) calculated as: 0.56*square root (sqrt) (TJC)+0.28*sqrt(SJC)+0.36*ln(CRP+1)+0.014*PGA+0.96. Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. A decrease in DAS28-CRP indicated an improvement in participant's condition.
LS mean calculated using a repeated measures model and adjusted for baseline + treatment + time + treatment * time.
-
Change From Baseline in C-Reactive Protein (CRP)
Time frame: Baseline, Days 7, 14, 21, 28, 35, 63, and 98
CRP is a biomarker associated with inflammation and structural damage. A negative change from baseline indicates improvement. LS mean calculated using a repeated measures model and adjusted for baseline + treatment + time + treatment * time.
-
Change From Baseline in Health Assessment Questionnaire (HAQ) Score
Time frame: Baseline, Days 35, 63, and 98
HAQ was a participant-reported questionnaire that consisted of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). The highest score for any question in a category was the score of that category unless special aids or devices or help from another person was required. Answers for at least 6 of the 8 disability domains were required to compute the participant's HAQ score. If the participant had scores for fewer than 6 categories, the HAQ score was considered missing. The HAQ score was calculated as the sum of the category scores divided by the number of categories scored, with a possible scores range from 0 to 3. Negative mean changes from baseline indicated improvement.
Sponsors and collaborators
Lead sponsor
Eli Lilly and Company
Industry
Registry information
Official study title
A Phase 1b/2 Multiple-Dose Safety Study and Pharmacokinetic/ Pharmacodynamic Study of LY2189102 in Patients With Rheumatoid Arthritis
Important dates
- Study start
- 2005
- Primary completion
- 2007
- Study completion
- 2007
- First posted
- Sep 26, 2006
- Registry last updated
- Feb 6, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Methotrexate and Metformin in Rheumatoid Arthritis Patients
NCT04196868
Arthritis, Arthritis, Rheumatoid
Bayonne, France
View Trial DetailsCharacterization of Breg Cells
NCT02615951
Arthritis, Arthritis, Rheumatoid
Montpellier, Hérault, France
View Trial DetailsStudy of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism
NCT05961267
Ankylosis, Arthritis
Bordeaux, France
View Trial DetailsDefining Stress REsilience And Mindfulness Effects in Rheumatoid Arthritis
NCT06276387
Arthritis, Arthritis, Rheumatoid
San Francisco, California, United States
View Trial Details